Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Inclusion Criteria: * Subjects with relapsing forms of MS defined by 2005 revised McDonald criteria * Patients with Expanded Disability Status Scale (EDSS) score of 0-6.5 Exclusion Criteria: * Patients with a manifestation of MS other than relapsing remitting MS * Patients with a history of chronic disease of the immune system other than MS such as known immunodeficiency syndrome * History or presence of malignancy in the last 5 years * Diabetic patients with moderate or severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy and uncontrolled diabetic patients * Diagnosis of macular edema during Screening Phase * Patients with active systemic bacterial, viral or fungal infections * Negative for varicella-zoster virus IgG antibodies at Screening * Patients who have been treated with cladribine, cyclophosphamide or mitoxantrone at any time * History of cardiovascular disorder * Women of child-baring potential and inadequate contraception Other protocol-defined inclusion/exclusion criteria may apply